Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Maravai LifeSciences Holdings, Inc. (MRVI)

14.035   -0.145 (-1.02%) 03-22 12:09
Open: 14.11 Pre. Close: 14.18
High: 14.3 Low: 14.01
Volume: 378,548 Market Cap: 3,585(M)

Technical analysis

as of: 2023-03-22 11:48:15 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 18.26     One year: 19.73
Support: Support1: 13.59    Support2: 11.3
Resistance: Resistance1: 15.63    Resistance2: 16.89
Pivot: 15.07
Moving Average: MA(5): 14.31     MA(20): 14.97
MA(100): 14.45     MA(250): 22.21
MACD: MACD(12,26): -0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 6.6     %D(3): 10.2
RSI: RSI(14): 42.7
52-week: High: 38.79  Low: 12.15
Average Vol(K): 3-Month: 1,332 (K)  10-Days: 1,118 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ MRVI ] has closed above bottom band by 13.5%. Bollinger Bands are 7.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 14.67 - 14.74 14.74 - 14.81
Low: 13.93 - 14.02 14.02 - 14.11
Close: 14.02 - 14.16 14.16 - 14.29

Company Description

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.

Headline News

Tue, 21 Mar 2023
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - Simply Wall St

Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On David Dreman - 3 ... - Nasdaq

Wed, 15 Mar 2023
Glenmede Trust Co. NA Has $347000 Stake in Maravai ... - MarketBeat

Thu, 09 Mar 2023
Will Maravai LifeSciences Holdings (MRVI) be a Long-Term Compounder in Your Portfolio? - Yahoo Finance

Mon, 06 Mar 2023
Maravai Reports Record Earnings - San Diego Business Journal

Sat, 04 Mar 2023
13 Most Undervalued Healthcare Stocks To Buy According To Hedge Funds - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 132 (M)
Shares Float 98 (M)
% Held by Insiders 0.4 (%)
% Held by Institutions 98.3 (%)
Shares Short 5,070 (K)
Shares Short P.Month 5,340 (K)

Stock Financials

EPS 4.71
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.29
Profit Margin (%) 26.2
Operating Margin (%) 68
Return on Assets (ttm) 18.6
Return on Equity (ttm) 81.8
Qtrly Rev. Growth -6.6
Gross Profit (p.s.) 5
Sales Per Share 6.89
EBITDA (p.s.) 4.91
Qtrly Earnings Growth -23.8
Operating Cash Flow 495 (M)
Levered Free Cash Flow 332 (M)

Stock Valuations

PE Ratio 2.98
PEG Ratio -0.3
Price to Book value 6.11
Price to Sales 2.04
Price to Cash Flow 3.73

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.